Freeline Therapeutics (FRLN)
NASDAQ: FRLN
· Real-Time Price · USD
6.49
0.01 (0.15%)
At close: Feb 16, 2024, 9:37 PM
Freeline Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 29.45M | 38.8M | 55.41M | 47.28M | 65.85M | 90M | 113.1M | 117.66M | 136.38M | 164.68M | 195.76M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | 1.33M | 1.21M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 2.15M | 2.22M | 2.18M | 3.46M | 1.89M | 3.36M | 4.13M | 2.92M | 2.08M | 2.69M | 1.66M |
Receivables | 2.82M | 3.12M | 1.53M | 1.23M | 2.96M | 2.66M | 2.53M | 2.21M | 17.32M | 17.33M | 16.74M |
Inventory | 768K | 1.06M | 3.77M | 17.64M | 4.04M | 2.14M | 4M | 6.42M | 1.79M | 1.56M | 1.6M |
Other Current Assets | 953K | 2.84M | 3.15M | 1.47M | 1.25M | 1.31M | 2.73M | 2M | 3.05M | 4.73M | 9.38M |
Total Current Assets | 34M | 45.81M | 63.87M | 67.63M | 74.1M | 96.11M | 122.35M | 128.29M | 158.54M | 188.3M | 223.48M |
Property-Plant & Equipment | 12.55M | 14.08M | 14.78M | 15.02M | 22.49M | 62.28M | 69.69M | 9.91M | 10.14M | 10.05M | 10.09M |
Goodwill & Intangibles | n/a | n/a | n/a | -1.33M | 3K | 4K | 6K | 8K | 10K | 11K | 16K |
Total Long-Term Assets | 15.22M | 16.84M | 17.5M | 19.01M | 25.97M | 66.02M | 73.82M | 12.83M | 12.23M | 12.75M | 11.76M |
Total Assets | 49.22M | 62.65M | 81.37M | 86.64M | 100.08M | 162.13M | 196.17M | 141.13M | 170.77M | 201.05M | 235.25M |
Account Payables | 7.78M | 6.88M | 12.45M | 10.06M | 9.96M | 7.88M | 9.14M | 5.19M | 5.67M | 4.55M | 5.53M |
Deferred Revenue | 7.13M | 8.88M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 2.29M | 2.84M | 2.75M | 2.66M | 2.88M | 11M | 7.41M | n/a | n/a | n/a | n/a |
Other Current Liabilities | 283K | 85K | 7.54M | 18.25M | 9.58M | 7.22M | 8.84M | 15.5M | 12.3M | 10.87M | 10.29M |
Total Current Liabilities | 17.48M | 18.68M | 22.74M | 30.97M | 22.42M | 26.1M | 25.39M | 20.68M | 17.97M | 15.42M | 15.82M |
Long-Term Debt | 1.7M | 1.96M | 2.64M | 3.26M | 9.08M | 46.41M | 52.22M | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 1.7M | 1.96M | 2.64M | 3.26M | 9.08M | 46.41M | 52.22M | n/a | n/a | n/a | n/a |
Total Liabilities | 19.18M | 20.64M | 25.38M | 34.23M | 31.49M | 72.5M | 77.61M | 20.68M | 17.97M | 15.42M | 15.82M |
Total Debt | 3.99M | 4.8M | 5.39M | 5.92M | 11.96M | 57.41M | 59.63M | n/a | n/a | n/a | n/a |
Common Stock | 137K | 137K | 137K | 137K | 137K | n/a | n/a | -9.61M | n/a | n/a | n/a |
Retained Earnings | -472.29M | -460.2M | -444.19M | -445.35M | -422.35M | -407.46M | -383.11M | -356.38M | -321.68M | -290.81M | -250.94M |
Comprehensive Income | -1.57M | -784K | -1.72M | -3.15M | -8.85M | -1.5M | 6.74M | 9.47M | 9.06M | 14.2M | 11.37M |
Shareholders Equity | 30.04M | 42.02M | 55.99M | 52.41M | 68.58M | 89.63M | 118.56M | 120.44M | 152.8M | 185.63M | 219.43M |
Total Investments | n/a | n/a | n/a | 1.33M | 1.21M | n/a | n/a | n/a | n/a | n/a | n/a |